Effect of the potassium channel opener WAY-133537 on the overactive bladder of spinalized rats

Neurourology and Urodynamics

Volumn 25, Issue 7, 2006, Pages 808-814

  Elzayat, Ehab ^a   Khaled, Sabri ^a   Kashiwabara, Takeshi ^a   Elhilali, Mostafa ^a   Corcos, Jacques ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Bladder overactivity; Potassium channel openers; Spinal cord injury

Indexed keywords

4 [3,4 DIOXO 2 (1,2,2 TRIMETHYLPROPYLAMINO) 1 CYCLOBUTENYLAMINO] 3 ETHYLBENZONITRILE; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; CONTROLLED STUDY; CYSTOMETROGRAPHY; CYSTOMETRY; DETRUSOR MUSCLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; NONHUMAN; OVERACTIVE BLADDER; PARAPLEGIA; RAT; SPINAL CORD INJURY;

ANIMALS; CORDOTOMY; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; FEMALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NITRILES; PARAPLEGIA; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER, OVERACTIVE;

EID: 33750610035     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20284     Document Type: Article

References (19)

1. Abdel-Karim AM, Bialecki RA, Elhilali MM. 2002. Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol 168:837-42.
2. Abrams P, Cardozo L, Fall M, et al. 2003. The standardisation of terminology in lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Urology 61:37-49.
3. Brading AF. 1997. A myogenic basis for the overactive bladder. Urology 50(Suppl 6A):57-67.
4. Brune ME, Fey TA, Brioni JD, et al. 2002. (-)-(9S)-9-(3-Bromo-4- fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): A novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. In vivo characterization. J Pharmacol Exp Ther 303:387-94.
5. Buckner SA, Milicic I, Daza A, et al. 2000. Pharmacological and molecular analysis of ATP-sensitive K(+) channels in the pig and human detrusor. Eur J Pharmacol 400:287-95.
6. Chappie CR, Yamanishi T, Chess-Williams R. 2002. Muscarinic receptor subtypes and management of the overactive bladder. Urology 60(5 Suppl 1):82-8.
7. Corcos J, Schick E. 2004. Prevalence of overactive bladder and incontinence in Canada. Can J Urol 11:2278-84.
8. Fabiyi AC, Gopalakrishnan M, Lynch JJ III, et al. 2003. In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats. BJU Int 91:284-90.
9. Foster CD, Speakman MJ, Fujii K, et al. 1989. The effects of cromakalim on the detrusor muscle of human and pig urinary bladder. Br J Urol 63:284-94.
10. Fryer RM, Preusser LC, Calzadilla SV, et al. 2004. (-)-(9S)-9-(3-Bromo-4- fluorophenyl)-2,3,5,6,7,9-hexahydrothieno [3,2-b] quinolin-8 (4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: Hemodynamic comparison to ZD-6169, WAY-133537, and Nifedipine in the anesthetized canine. J Cardiovasc Pharmacol 44:137-47.
11. Heppner TJ, Bonev AD, Nelson MT. 1997. Ca2+-activated K+ channels regulate action potential repolarization in urinary bladder smooth muscle. Am J PhysiolCell Physiol 273:C110-7.
12. Howe BB, Halterman TJ, Yochim CL, et al. 1995. ZENECA ZD6169: A novel KATP channel opener with in vivo selectivity for urinary bladder. J Pharmacol Exp Ther 274:884-90.
13. Lynch JJ III, Brune ME, Lubbers NL, et al. 2003. K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats. Life Sci 72:1931-41.
14. Mills IW, Greenland JE, McMurray G, et al. 2000. Studies of the pathophysiology of idiopathic detrusor instability: The physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 163:646-51.
15. Milsom I, Abrams P, Cardozo L, et al. 2001. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-6.
16. Petkov GV, Heppner TJ, Bonev AD, et al. 2001. Low levels of K (ATP) channel activation decrease excitability and contractility of urinary bladder. Am J Physiol Regul Integr Comp Physiol 280:R1427-33.
17. Stewart WF, Van Rooyen JB, Cundiff GW, et al. 2003. Prevalence and burden of overactive bladder in the United States. World J Urol 20:327-36.
18. Wojdan A, Freeden C, Woods M, et al. 1999. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J Pharmacol Exp Ther 289:1410-8.
19. Zvara P, Sahi S, Hassouna MM. 1998. An animal model for the neuromodulation of neurogenic bladder dysfunction. Br J Urol 82:267-71.